 Antibodies, Bispecific
"Antibodies, Bispecific" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.
| Descriptor ID |
D018033
|
| MeSH Number(s) |
D12.776.124.486.485.114.125 D12.776.124.790.651.114.134 D12.776.377.715.548.114.134
|
| Concept/Terms |
Antibodies, Bispecific- Antibodies, Bispecific
- Bispecific Antibodies
- Bifunctional Antibodies
- Antibodies, Bifunctional
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Bispecific".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Bispecific".
This graph shows the total number of publications written about "Antibodies, Bispecific" by people in this website by year, and whether "Antibodies, Bispecific" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 0 | 1 | | 2012 | 0 | 1 | 1 | | 2013 | 2 | 1 | 3 | | 2014 | 1 | 0 | 1 | | 2015 | 1 | 0 | 1 | | 2016 | 1 | 0 | 1 | | 2018 | 3 | 0 | 3 | | 2019 | 2 | 1 | 3 | | 2020 | 2 | 0 | 2 | | 2021 | 3 | 0 | 3 | | 2022 | 0 | 2 | 2 | | 2023 | 4 | 0 | 4 | | 2024 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibodies, Bispecific" by people in Profiles.
-
Crombie JL, Graff T, Falchi L, Karimi YH, Bannerji R, Nastoupil L, Thieblemont C, Ursu R, Bartlett N, Nachar V, Weiss J, Osterson J, Patel K, Brody J, Abramson JS, Lunning M, Shah NN, Ayed A, Kamdar M, Parsons B, Caimi P, Flinn I, Herrera A, Sharman J, McKenna M, Armand P, Kahl B, Smith S, Zelenetz A, Budde LE, Hutchings M, Phillips T, Dickinson M. Consensus recommendations on the management of toxicity associated with CD3?CD20 bispecific antibody therapy. Blood. 2024 04 18; 143(16):1565-1575.
-
Chen X, Wong OK, Reiman L, Sherbenou DW, Post L. CD38 x ICAM-1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphoma. Mol Cancer Ther. 2024 Feb 01; 23(2):127-138.
-
Major A, Kamdar M. Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas. Hematology Am Soc Hematol Educ Program. 2023 Dec 08; 2023(1):370-381.
-
Astermark J, Buckner TW, Frenzel L, Hatswell AJ, You X, Liu H, Goodman E, Santos S, Hawes C, Hinds D, Klamroth R. Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis. Haemophilia. 2023 Jul; 29(4):1087-1094.
-
Hogan LE, Brown PA, Ji L, Xu X, Devidas M, Bhatla T, Borowitz MJ, Raetz EA, Carroll A, Heerema NA, Zugmaier G, Sharon E, Bernhardt MB, Terezakis SA, Gore L, Whitlock JA, Hunger SP, Loh ML. Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse. J Clin Oncol. 2023 09 01; 41(25):4118-4129.
-
Queudeville M, Stein AS, Locatelli F, Ebinger M, Handgretinger R, G?kbuget N, Gore L, Zeng Y, Gokani P, Zugmaier G, Kantarjian HM. Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2023 05 01; 129(9):1384-1393.
-
Meric-Bernstam F, Beeram M, Hamilton E, Oh DY, Hanna DL, Kang YK, Elimova E, Chaves J, Goodwin R, Lee J, Nabell L, Rha SY, Mayordomo J, El-Khoueiry A, Pant S, Raghav K, Kim JW, Patnaik A, Gray T, Davies R, Ozog MA, Woolery J, Lee KW. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet Oncol. 2022 12; 23(12):1558-1570.
-
Wang M, Yang JC, Mitchell PL, Fang J, Camidge DR, Nian W, Chiu CH, Zhou J, Zhao Y, Su WC, Yang TY, Zhu VW, Millward M, Fan Y, Huang WT, Cheng Y, Jiang L, Brungs D, Bazhenova L, Lee CK, Gao B, Xu Y, Hsu WH, Zheng L, J?nne PA. Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Cancer Discov. 2022 07 06; 12(7):1676-1689.
-
Fu S, Corr BR, Culm-Merdek K, Mockbee C, Youssoufian H, Stagg R, Naumann RW, Wenham RM, Rosengarten RD, Benjamin L, Hamilton EP, Moore KN. Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. J Clin Oncol. 2022 08 10; 40(23):2568-2577.
-
Verneris MR, Ma Q, Zhang J, Keating A, Tiwari R, Li J, Yang H, Agarwal A, Pacaud L. Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia. Blood Adv. 2021 12 14; 5(23):5387-5395.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|